DYNE-251

DRUG2 trials

Sponsors

Dyne Therapeutics Inc., Dyne Therapeutics

Conditions

Duchenne Muscular Dystrophy (DMD)Duchenne muscular dystrophy

Phase 1

Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

Active, not recruitingNCT05524883

Dyne TherapeuticsDuchenne Muscular Dystrophy (DMD)

Start: 2022-08-12End: 2031-09-01Updated: 2026-08-11

A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study Assessing Safety, Tolerability, Pharmacodynamics, Efficacy, and Pharmacokinetics of DYNE-251 Administered to Participants with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

Active, not recruitingCTIS2023-510351-31-00

Dyne Therapeutics Inc.Duchenne muscular dystrophy

Start: 2023-01-06Target: 16Updated: 2025-06-16